Challenges of cytoreduction in porta hepatis in surgery for advanced ovarian cancer

• Published in: Gynecologic oncology reports Vol. 54; p. 101413
• Main Authors: Raju, Kvvn, Jonnada, Pavan Kumar, Badude, Madhunarayana, Nekkanti, Siddarth, Nusrath, Syed, Keshri, Pradeep, Ram Reddy, Raghu
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01.08.2024; Elsevier
• Subjects: Correspondence; Cytoreductive surgery; Oncological outcomes; Ovarian Cancer Surgery; Porta hepatis clearance; Oncological outcomes; Cytoreductive surgery; Porta hepatis clearance; Ovarian Cancer Surgery
• ISSN: 2352-5789; 2352-5789
• DOI: 10.1016/j.gore.2024.101413

Advanced ovarian cancer often necessitates aggressive surgical intervention, including cytoreduction of the porta hepatis, which poses significant challenges due to the intricate anatomical structures involved. This surgical video aims to illustrate these challenges and demonstrate effective techniques for clearance of critical structures such as the portal vein (PV), common bile duct (CBD), accessory left hepatic artery (Acc. LHA), obliterated umbilical vein (OUV), inferior vena cava (IVC), and foramen of Winslow. The surgical procedure depicted in the video involved meticulous dissection and identification of anatomical landmarks to access the porta hepatis. Techniques for safe clearance of the PV, CBD, Acc. LHA, OUV, IVC, and foramen of Winslow were employed and are highlighted in detail. Emphasis was placed on preserving vascular integrity and minimizing intraoperative complications. The video demonstrates the complexities associated with cytoreduction of the porta hepatis in advanced ovarian cancer surgery and offers insights into overcoming these challenges. By utilizing precise surgical techniques and careful anatomical consideration, successful clearance of critical structures can be achieved, thereby optimizing patient outcomes and minimizing postoperative complications. This educational resource provides valuable guidance for surgeons encountering similar challenges in the management of advanced ovarian cancer.